Concepedia

Paweł Wiechno

PW

35

Publications

6.1K

Citations

24

H-Index

2007

Active since

Affiliations

The Maria Sklodowska-Curie National Research Institute of Oncology(Current)

Centrum Onkologii

Comprehensive Cancer Centers of Nevada

Merck & Co., Inc., Rahway, NJ, USA (United States)

P.A. Hertzen Moscow Oncology Research Institute

Paweł Wiechno is an author at The Maria Sklodowska-Curie National Research Institute of Oncology specializing in oncology, urology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2007–2024

35

Publications

35

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Chris Parker, Sten Nilsson, Daniel Heinrich et al. · New England Journal of Medicine · 2013 · 3.3K citations

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

Oliver Sartor, Robert L. Coleman, Sten Nilsson et al. · The Lancet Oncology · 2014 · 485 citations

, , +8

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

Noel W. Clarke, Paweł Wiechno, B. Yа. Alekseev et al. · The Lancet Oncology · 2018 · 405 citations · Full text

, , +5

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

David F. McDermott, Jae‐Lyun Lee, Marek Ziobro et al. · Journal of Clinical Oncology · 2021 · 277 citations · Full text

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer

Thomas Powles, James W.F. Catto, Matthew D. Galsky et al. · New England Journal of Medicine · 2024 · 245 citations · Full text

Rows per page

1–5 of 35